CLNN (clene.com) Market Value to Book Value Ratio
Clene Inc. (CLNN) is establishing targeted supply chains for neurological drugs, mitigating disruption risks through counterparty diversification, which locks in returns at -1.98. This price chart confirms the asset's market dynamics. The company is developing gold-crystal nanotherapy to maintain neuronal energy in ALS patients. The synthesis of CNS drugs is conducted in perfectly validated sterile facilities.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_CLNN_-_Clene-Inc._-_Capitalization-to-Book-Value-Ratio "CLNN Clene Nanomedicine Market Capitalization to Book Value Ratio (07/04/2022 - 10/27/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Clene Inc. (CLNN)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Initial company analysis:Clene Inc, CLNN
Clene Inc. is developing innovative neuroprotection for ALS therapy, leveraging high patient loyalty and scientific authority. This indicator compares the market value of all shares with the book value of net assets. By analyzing the company's valuation history via the P/B ratio, one can determine the degree of business overvaluation relative to its tangible resources. This price action reflects market expectations regarding regulatory decisions. Investors utilize this gap to identify entry points upon a return to historical medians.
Direct competitors
Market Value to Book Value Ratio Biogen Inc.|NBIX (neurocrine.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|Biohaven Corp (BHVN) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio AMLX|Market Cap to Net Assets Ratio TRVI|Market Value to Book Value Ratio Praxis Precision Medicines, Inc. (PRAX)|Market Value to Book Value Ratio Anavex (AVXL)|CBLL: Market Capitalization to Book Value Ratio|Prothena - Market-to-Book Ratio|Alector Therapeutics (ALEC) - Market Value to Book Value Ratio|ANNX - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio OMER|Market-to-Book Ratio Neurogene Inc|ACIU - Market Cap to Net Assets Ratio|Market Value to Book Value Voyager Corp|NMRA (Neumora Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value SCLX (scilexholding.com)|TVGN - Market Value to Book Value Ratio|Capitalization to Book Value Ratio Alpha Cognition Inc ACOG|CGTX: Market Capitalization to Book Value Ratio|Inhibikase Pharma (IKT) - Market Cap to Net Assets Ratio|Cassava Sciences, Inc. - Market Cap to Net Assets Ratio|Assertio (ASRT) - Market Capitalization to Book Value|Market Capitalization to Book Value Ratio COYA|Market Cap to Net Assets Ratio VTGN|Market Value to Book Value Ratio Ovid Therapeutics Inc. (OVID)|Market Value to Book Value Ratio ABOS (Acumen Pharmaceuticals, Inc)|CRVO - Market Value to Book Value Ratio|Alterity Therapeutics Ltd. - Capitalization to Book Value Ratio|PepGen Corp (PEPG) - Market Value to Book Value Ratio|JUNS: Capitalization to Book Value Ratio|Market Value to Book Value Ratio Relmada|Annovis Bio Corporation (ANVS) - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio GRCE (Grace Therapeutics Inc)|Market-to-Book Ratio fireflyneuro.com (AIFF)|Market Cap to Net Assets Ratio KLTO|Market Capitalization to Book Value Ratio NRSN (neurosense-tx.com)|Market Value to Book Value Ratio Reviva Pharmaceuticals Holdings|MetaVia Inc. - Market Value to Book Value|NRXS (NeurAxis, Inc.) - Market Value to Book Value Ratio|HSDT - Market-to-Book Ratio|PASG (passagebio.com) - Market Capitalization to Book Value Ratio|NEUP (Neuphoria Therapeutics) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Minerva Neurosciences Corp|Market Value to Book Value Ratio Athira Pharma Corp|Addex Therapeutics - Market Capitalization to Book Value Ratio|Market-to-Book Ratio ALZN (alzamend.com)|CYCN - Market Value to Book Value Ratio|Capitalization to Book Value Ratio Protagenic Therapeutics Inc. PTIX|KTTA (Pasithea) - Market Capitalization to Book Value Ratio|Cortigent, Inc. (CRGT) - Market-to-Book Ratio|Market Cap to Net Assets Ratio Avenue Therapeutics ATXI|brainstorm-cell.com (BCLI) - Market Value to Book Value|CARA: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value CHRO|Market Value to Book Value Ratio Eliem Therapeutics ELYM|Capitalization to Book Value Ratio intracellulartherapies.com (ITCI)|Longboard Pharmaceuticals - Market Capitalization to Book Value Ratio|MRNS - Market Cap to Net Assets Ratio|Market Cap to Net Assets Ratio NKGN (NKGen Biotech)|NRBO - Market Capitalization to Book Value|SAGE (Sage Therapeutics, Inc) - Market Capitalization to Book Value Ratio|SNPX (Synaptogenix, Inc) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Trevena, Inc.|Market Value to Book Value Ratio VIGL|Market Value to Book Value Ratio Anew Medical, Inc. WENA|Capitalization to Book Value Ratio CERE (Cerevel Therapeutics Inc)